Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Librera OncoLink / Repaso de Diarios / Cáncer de Próstata
Paulson DP, Lin GH, Hinshaw W, and Stephani S
The Uro-Oncology Research Group
Ultima Vez Modificado: 18 de agosto del 2006
Reviewed by: Drew Moghanaki MD, MPH
Source: The Journal of Urology 1982. Sep;128(3):502-4.
Initially, 59 and 47 patients were randomized to radiation and prostatectomy, respectively. However, there were patients in both groups who failed to receive their assigned treatments, and cross-over to the opposite treatment arm was allowed.
Analysis was performed by treatment given, and not by treatment intention.
The primary endpoint of failure was recorded as any 2 consecutive rises in PAP levels, or abnormal chest x-ray or bone scan.
Follow-up consisted of periodic physical examination, PAP levels, CXR, and bone scans. The trial was closed early due to inadequate funding, and after study closure, follow-up appointments were only encouraged, but not required.
Other problems include the 4-envelope randomization scheme, which is fraught with potential selection bias, as it allows the opportunity to know the randomization in up to 50% of patients. In addition, not all institutions completed the 4-patient randomization, raising concern for physician selection bias. The analysis was not intent-to-treat and permitted cross-over, neither of which is generally accepted practice in randomized studies. Pathologic stage C patients were excluded from the surgical arm but allowed in the radiation arm, and the rate of failure in the radiotherapy arm resembles a pattern more consistent with stage C patients. No median follow-up time is given, and no overall survival data are reported.
The authors do attempt to describe the radiotherapy technique; however, the information provided suggests a non-standard fractionation scheme during the whole-pelvis component of treatment. Additionally, although unpublished, it has been suggested that the vast majority of patients received only 6,500 cGy, which by today's standards is known to be sub-therapeutic.
There was no tissue validation reported for relapse, and no quality assurance was maintained for abnormal bone scans. Multiple reports have demonstrated a >30% rate of false positive bone scans in patients treated for prostate cancer. Additionally, it has become clear over time that elevated PAP levels can result from radiotherapy to bone, confounding this variable as a marker of failure in the radiotherapy group.
Regarding the current utility of this study in the treatment decision-making process for patients with locally confined prostate adenocarcinoma, it should be emphasized that the surgical procedure used, prostatectomy, has since been replaced with radical prostatectomy as the standard uro-oncologic approach for prostate cancer. Additionally, a 40% rate of incontinence among patients undergoing surgery is considered unacceptably high by today's standards.
It is unfortunate that the methodologic flaws present within the study preclude any meaningful conclusions regarding prostatectomy versus radiotherapy in organ-confined prostate cancer. Modern retrospective analyses have repeatedly suggested equivalency of surgery versus radiation in this patient population.3 Ultimately, however, it would be useful if an appropriately designed prospective randomized trial addressing this question could be conducted.
1 Re: Radical surgery versus radiotherapy for adenocarcinoma of the prostate. Byhardt RW, Greenlaw RH, Jensen R, Nag S, Roswit B, Stephani S, Woodward K. Journal of Urology 1983 Dec;130(6):1205-6.
2 More on the Uro-Oncology Research Group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1988 May;14(5):1053-4.
3 Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005 Jul 27;294(4):440-7.
3D mammography, also known as digital tomosynthesis, is a new technology aimed at having better detection of abnormalities and fewer false positives. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

